Evidence map›Paper›PMID 35086613›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022

Surveillance of leishmaniasis cases from 15 European centres, 2014 to 2019: a retrospective analysis.

Gert Van der Auwera, Leigh Davidsson, Pierre Buffet, Marie-Thérèse Ruf, Marina Gramiccia, Stefania Varani, Carmen Chicharro, Aldert Bart, Gundel Harms, Peter L Chiodini and 16 more

Open access · diamondAbstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Evaluation of Multi-Target Genotyping (ITS-Pathogens (Basel, Switzerland) · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Leishmaniasis.Nature reviews. Disease primers · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Temporal and spatial analysis of visceral leishmaniasis in Brazil, by age group and sex: an ecological study, 2013-2022.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Typing ofParasitology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 19 institutions in 12 countries.

Gert Van der AuweraInstitute of Tropical Medicine, Antwerp, Belgium.
Leigh DavidssonThe Public Health Agency of Sweden, Solna, Sweden.
Pierre BuffetService des maladies infectieuses et tropicales, AP-HP, Hopital Necker, Paris, France.
Marie-Thérèse RufSwiss Tropical and Public Health Institute, Basel, Switzerland.
Marina GramicciaIstituto Superiore di Sanità, Rome, Italy.
Stefania VaraniIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Carmen ChicharroInstituto de Salud Carlos III, Madrid, Spain.
Aldert BartAmsterdam University Medical Centre, Amsterdam, the Netherlands.
Gundel HarmsInstitute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt - Universität zu Berlin, Berlin, Germany.
Peter L ChiodiniHospital for Tropical Diseases, London, United Kingdom.
Hanne BrekkeOslo University Hospital, Oslo, Norway.
Florence Robert-GangneuxUniv Rennes, CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, Rennes, France.
Sofia CortesGlobal Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisbon, Portugal.
Jaco J VerweijMicrovida Laboratory for Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands.
Alessandra ScarabelloNational Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy.
Sara Karlsson SöbirkDivision of Infection Medicine, Lund University, Lund, Sweden.
Romain GuéryHôpital privé du Confluent, Nantes, France.
Saskia van HentenInstitute of Tropical Medicine, Antwerp, Belgium.
Trentina Di MuccioIstituto Superiore di Sanità, Rome, Italy.
Elena CarraIstituto Zooprofilattico Sperimentale della Lombardia e dell' Emilia-Romagna 'Bruno Ubertini', Brescia, Italy.
Pieter van ThielAmsterdam University Medical Centre, Amsterdam, the Netherlands.
Martin VandeputteInstitute of Tropical Medicine, Antwerp, Belgium.
Valeria GaspariIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Johannes BlumSwiss Tropical and Public Health Institute, Basel, Switzerland.
LeishMan Surveillance networkThe members of the network are listed under Investigators.
LeishMan Surveillance Network members who contributed to this article (in addition to authors above)
Instituut voor Tropische Geneeskunde · BEAzienda USL di Bologna · ITIstituto Superiore di Sanità · ITAssistance Publique – Hôpitaux de Paris · FRÉcole des Hautes Études en Santé Publique · FRElisabeth-TweeSteden Ziekenhuis · NLEscuela Nacional de Sanidad · ESFreie Universität Berlin · DEHôpital privé du Confluent · FRHospital for Tropical Diseases · GBIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITIstituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini" · ITLibrary Network · USLund University · SEOslo University Hospital · NOPublic Health Agency of Sweden · SESwiss Tropical and Public Health Institute · CHUniversidade Nova de Lisboa · PTUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundSurveillance of human leishmaniasis in Europe is mostly limited to country-specific information from autochthonous infections in the southern part. As at the end of 2021, no integrated analysis has been performed for cases seen across centres in different European countries.AimTo provide a broad perspective on autochthonous and imported leishmaniasis cases in endemic and non-endemic countries in Europe.MethodsWe retrospectively collected records from cutaneous, mucosal and visceral leishmaniasis cases diagnosed in 15 centres between 2014 and 2019. Centres were located in 11 countries: Belgium, France, Germany, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom. Data on country of infection, reason for travelling, infecting species, age and sex were analysed.ResultsWe obtained diagnostic files from 1,142 cases, of which 76%, 21% and 3% had cutaneous, visceral, and mucosal disease, respectively. Of these, 68% were men, and 32% women, with the median age of 37 years (range: 0-90) at diagnosis. Visceral leishmaniasis was mainly acquired in Europe (88%; 167/190), while cutaneous leishmaniasis was primarily imported from outside Europe (77%; 575/749). Sixty-two percent of cutaneous leishmaniasis cases from outside Europe were from the Old World, and 38% from the New World. Geographic species distribution largely confirmed known epidemiology, with notable exceptions.ConclusionsOur study confirms previous reports regarding geographic origin, species, and traveller subgroups importing leishmaniasis into Europe. We demonstrate the importance of pooling species typing data from many centres, even from areas where the aetiology is presumably known, to monitor changing epidemiology.

Indexed as

LeishmaniasisLeishmaniasis, CutaneousLeishmaniasis, VisceralAdolescentAdultAgedAged, 80 and overChildChild, PreschoolEuropeFemaleHumansInfantInfant, NewbornMaleMiddle AgedauthochthonousEuropeimportedLeishmanialeishmaniasissurveillancetravel

Identifiers

PMID35086613
PMCPMC8796293
OpenAlexW4210462634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.